{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:32:21Z","timestamp":1785411141898,"version":"3.56.0"},"posted":{"date-parts":[[2025,11,8]]},"group-title":"Immunology","reference-count":72,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"award":["R01-AI125421-01A1"],"award-info":[{"award-number":["R01-AI125421-01A1"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]},{"award":["1RO1AI141229"],"award-info":[{"award-number":["1RO1AI141229"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,11,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Gonorrhea is increasingly resistant to treatment and has been labelled an urgent threat due to the diminishing effectiveness of existing therapeutics. To address this challenge, we targeted the\n                  <jats:italic>Neisseria gonorrhoeae<\/jats:italic>\n                  transferrin binding protein B (TbpB), which is critical for iron acquisition and neisserial growth, as a vaccine target. Building on previous studies investigating the application of TbpB as an immunogen against various bacterial pathogens, we aimed to optimize this antigen for a broad protective effect. We compared the efficacy of wild type TbpB immunogens with engineered TbpB mutants that do not bind human transferrin (hTf) using infection studies in transgenic mice expressing hTf, which were required because the strict specificity of neisserial TbpB precludes its complexing with non-human transferrin. Comprehensive biophysical analyses confirmed that the introduced single residue mutations abolished hTf binding without compromising antigen structure. Immunization with the mutant antigens conferred increased resistance to infection by\n                  <jats:italic>N. gonorrhoeae<\/jats:italic>\n                  relative to that provided by the wild-type antigen in the humanized mice. When considering effector functions of the humoral response, we observed that the mutated antigen elicited more effective bactericidal and function-neutralizing activity. Through strategic mutations, we therefore enhanced vaccine effectiveness in a physiologically relevant model without significantly affecting the structure or immunogenicity of the antigen. This study highlights the use of rational structure-guided antigen design to drive effective immune responses and the potential interference of immunogen binding to host factors, and reinforces the utility of targeting TbpB in a gonococcal vaccine.\n                <\/jats:p>","DOI":"10.1101\/2025.11.06.685839","type":"posted-content","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T17:10:13Z","timestamp":1762621813000},"source":"Crossref","is-referenced-by-count":0,"title":["Structure-based engineering of a nutrient acquisition protein enhances neutralizing antibodies and protection for the development of a gonococcal vaccine"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2420-6559","authenticated-orcid":false,"given":"Natalie Y.T.","family":"Au","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0373-8399","authenticated-orcid":false,"given":"En Ze L.","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie E.","family":"Fegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Epshita A.","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey X.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dixon","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura-lee","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine C.L.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4029-3296","authenticated-orcid":false,"given":"Anthony B.","family":"Schryvers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1477-3616","authenticated-orcid":false,"given":"Scott D.","family":"Gray-Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9883-6145","authenticated-orcid":false,"given":"Trevor F.","family":"Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2025111106000702000_2025.11.06.685839v1.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2097"},{"key":"2025111106000702000_2025.11.06.685839v1.2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0155-7"},{"key":"2025111106000702000_2025.11.06.685839v1.3","first-page":"1","article-title":"Impact and effectiveness of meningococcal vaccines: A review","volume":"41","year":"2017","journal-title":"Rev. Panam. Salud Publica\/Pan Am. J. Public Heal"},{"key":"2025111106000702000_2025.11.06.685839v1.4","doi-asserted-by":"crossref","first-page":"106228","DOI":"10.1016\/j.jinf.2024.106228","article-title":"Effectiveness and duration of protection of primary and booster immunisation against meningococcal serogroup C disease with meningococcal conjugate C and ACWY vaccines: Systematic review","volume":"89","year":"2024","journal-title":"J. Infect"},{"key":"2025111106000702000_2025.11.06.685839v1.5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1071\/SH19061","article-title":"Epidemiology of Gonorrhea: A Global Perspective","volume":"16","year":"2019","journal-title":"Sex Heal"},{"key":"2025111106000702000_2025.11.06.685839v1.6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00858"},{"key":"2025111106000702000_2025.11.06.685839v1.7","first-page":"1911","article-title":"Morbidity and Mortality Weekly Report Update to CDC\u2019s Treatment Guidelines for Gonococcal Infection, 2020","volume":"69","year":"2020","journal-title":"US Dep. Heal. Hum. Serv. Dis. Control Prev"},{"key":"2025111106000702000_2025.11.06.685839v1.8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00858"},{"key":"2025111106000702000_2025.11.06.685839v1.9","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2011.00065"},{"key":"2025111106000702000_2025.11.06.685839v1.10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003800"},{"key":"2025111106000702000_2025.11.06.685839v1.11","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab450"},{"key":"2025111106000702000_2025.11.06.685839v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31449-6"},{"key":"2025111106000702000_2025.11.06.685839v1.13","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00031-8"},{"key":"2025111106000702000_2025.11.06.685839v1.14","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf077"},{"key":"2025111106000702000_2025.11.06.685839v1.15","first-page":"61","article-title":"Effectiveness of MenB-4C vaccine against gonorrhea: a systematic review and meta-analysis","volume":"231","year":"2024","journal-title":"J. Infect. Dis"},{"key":"2025111106000702000_2025.11.06.685839v1.16","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx180.001"},{"key":"2025111106000702000_2025.11.06.685839v1.17","doi-asserted-by":"crossref","first-page":"312","DOI":"10.14745\/ccdr.v51i08a04","article-title":"Effectiveness of the four-component protein-based meningococcal vaccine against Neisseria gonorrhoeae infections: Mounting evidence and public health implications for Canada","volume":"51","year":"2025","journal-title":"Canada Commun. Dis. Rep"},{"key":"2025111106000702000_2025.11.06.685839v1.18","doi-asserted-by":"publisher","DOI":"10.1080\/10409238.2017.1293606"},{"key":"2025111106000702000_2025.11.06.685839v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2009.06.029"},{"key":"2025111106000702000_2025.11.06.685839v1.20","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.2251"},{"key":"2025111106000702000_2025.11.06.685839v1.21","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.1998.00710.x"},{"key":"2025111106000702000_2025.11.06.685839v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(93)90045-Y"},{"key":"2025111106000702000_2025.11.06.685839v1.23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41541-024-01054-0","article-title":"Rational selection of TbpB variants yields a bivalent vaccine with broad coverage against Neisseria gonorrhoeae","volume":"10","year":"2025","journal-title":"npj Vaccines"},{"key":"2025111106000702000_2025.11.06.685839v1.24","doi-asserted-by":"crossref","first-page":"126709","DOI":"10.1016\/j.vaccine.2025.126709","article-title":"Adjuvant-dependent impacts on vaccine-induced humoral responses and protection in preclinical models of nasal and genital colonization by pathogenic Neisseria","volume":"48","year":"2025","journal-title":"Vaccine"},{"key":"2025111106000702000_2025.11.06.685839v1.25","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.02572-14"},{"key":"2025111106000702000_2025.11.06.685839v1.26","doi-asserted-by":"publisher","DOI":"10.3391\/mbi.2014.5.1.01"},{"key":"2025111106000702000_2025.11.06.685839v1.27","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00781-07"},{"key":"2025111106000702000_2025.11.06.685839v1.28","doi-asserted-by":"publisher","DOI":"10.1110\/ps.072914007"},{"key":"2025111106000702000_2025.11.06.685839v1.29","doi-asserted-by":"publisher","DOI":"10.1038\/S41586-024-07487-W"},{"key":"2025111106000702000_2025.11.06.685839v1.30","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.68.9.4938-4947.2000"},{"key":"2025111106000702000_2025.11.06.685839v1.31","doi-asserted-by":"crossref","unstructured":"Bates, T. A. , Gurmessa, S. K. , Weinstein, J. B. , Trank-Greene, M. , Wrynla, X. H. , Anastas, A. , Anley, T. W. , Hinchliff, A. , Shinde, U. , Burke, J. E. & Tafesse, F. G . Biolayer interferometry for measuring the kinetics of protein\u2013protein interactions and nanobody binding. Nat. Protoc. 20, (2024).","DOI":"10.1038\/s41596-024-01079-8"},{"key":"2025111106000702000_2025.11.06.685839v1.32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0280077"},{"key":"2025111106000702000_2025.11.06.685839v1.33","doi-asserted-by":"publisher","DOI":"10.1103\/PhysRevLett.131.218401"},{"key":"2025111106000702000_2025.11.06.685839v1.34","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw288"},{"key":"2025111106000702000_2025.11.06.685839v1.35","doi-asserted-by":"crossref","unstructured":"Gulati, S. , Mcquillen, D. P. , Mandrell, R. E. , Jani, D. B. & Rice, P. A . Immunogenicity of Neisseria gonorrhoeae Lipooligosaccharide Epitope 2C7, Widely Expressed In Vivo with No Immunochemical Similarity to Human. (1996).","DOI":"10.1093\/infdis\/174.6.1223"},{"key":"2025111106000702000_2025.11.06.685839v1.36","doi-asserted-by":"crossref","unstructured":"Gulati, S. , Beurskens, F. J. , de Kreuk, B. J. , Roza, M. , Zheng, B. , Deoliveira, R. B. , Shaughnessy, J. , Nowak, N. A. , Taylor, R. P. , Botto, M. , He, X. , Ingalls, R. R. , Woodruff, T. M. , Song, W. C. , Schuurman, J. , Rice, P. A. & Ram, S . Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody. PLoS Biol. 17, (2019).","DOI":"10.1371\/journal.pbio.3000323"},{"key":"2025111106000702000_2025.11.06.685839v1.37","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.13760"},{"key":"2025111106000702000_2025.11.06.685839v1.38","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02579-19"},{"key":"2025111106000702000_2025.11.06.685839v1.39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191962"},{"key":"2025111106000702000_2025.11.06.685839v1.40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00858"},{"key":"2025111106000702000_2025.11.06.685839v1.41","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1128\/iai.65.1.55-63.1997","article-title":"Evaluation of recombinant transferrin-binding protein B variants from Neisseria meningitidis for their ability to induce cross-reactive and bactericidal antibodies against a genetically diverse collection of serogroup B strains","volume":"65","year":"1997","journal-title":"Infect. Immun"},{"key":"2025111106000702000_2025.11.06.685839v1.42","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1128\/iai.62.7.2984-2990.1994","article-title":"Immune responses in humans and animals to meningococcal transferrin-binding proteins: Implications for vaccine design","volume":"62","year":"1994","journal-title":"Infect. Immun"},{"key":"2025111106000702000_2025.11.06.685839v1.43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.1988.tb00095.x"},{"key":"2025111106000702000_2025.11.06.685839v1.44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.1988.tb00029.x"},{"key":"2025111106000702000_2025.11.06.685839v1.45","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.1998.00710.x"},{"key":"2025111106000702000_2025.11.06.685839v1.46","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.13.125"},{"key":"2025111106000702000_2025.11.06.685839v1.47","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1128\/iai.63.3.884-890.1995","article-title":"Evaluation of transferrin-binding protein 2 within the transferrin-binding protein complex as a potential antigen for future meningococcal vaccines","volume":"63","year":"1995","journal-title":"Infect. Immun"},{"key":"2025111106000702000_2025.11.06.685839v1.48","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.7.3945-3953.2005"},{"key":"2025111106000702000_2025.11.06.685839v1.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.07.038"},{"key":"2025111106000702000_2025.11.06.685839v1.50","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.206102"},{"key":"2025111106000702000_2025.11.06.685839v1.51","doi-asserted-by":"publisher","DOI":"10.1002\/mbo3.254"},{"key":"2025111106000702000_2025.11.06.685839v1.52","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.206102"},{"key":"2025111106000702000_2025.11.06.685839v1.53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23276-8"},{"key":"2025111106000702000_2025.11.06.685839v1.54","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1306441"},{"key":"2025111106000702000_2025.11.06.685839v1.55","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22284"},{"key":"2025111106000702000_2025.11.06.685839v1.56","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003470"},{"key":"2025111106000702000_2025.11.06.685839v1.57","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.05604-11"},{"key":"2025111106000702000_2025.11.06.685839v1.58","doi-asserted-by":"crossref","first-page":"16009","DOI":"10.1038\/nmicrobiol.2016.9","article-title":"Slam is an outer membrane protein that is required for the surface display of lipidated virulence factors in Neisseria","volume":"1","year":"2016","journal-title":"Nat. Microbiol"},{"key":"2025111106000702000_2025.11.06.685839v1.59","doi-asserted-by":"publisher","DOI":"10.1107\/S0909049511019431"},{"key":"2025111106000702000_2025.11.06.685839v1.60","first-page":"125","article-title":"XDS","volume":"D66","year":"2009","journal-title":"Biol. Crystallogr"},{"key":"2025111106000702000_2025.11.06.685839v1.61","doi-asserted-by":"publisher","DOI":"10.1107\/S2059798319011471"},{"key":"2025111106000702000_2025.11.06.685839v1.62","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03819-2"},{"key":"2025111106000702000_2025.11.06.685839v1.63","doi-asserted-by":"publisher","DOI":"10.1002\/pro.3865"},{"key":"2025111106000702000_2025.11.06.685839v1.64","doi-asserted-by":"publisher","DOI":"10.1107\/S0907444910007493"},{"key":"2025111106000702000_2025.11.06.685839v1.65","doi-asserted-by":"publisher","DOI":"10.1002\/bmb.20966"},{"key":"2025111106000702000_2025.11.06.685839v1.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2005.01.016"},{"key":"2025111106000702000_2025.11.06.685839v1.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2016.02.001"},{"key":"2025111106000702000_2025.11.06.685839v1.68","unstructured":"Nanotemper. Tycho NT.6 Application Guide. NanoTemper Technol. GmbH (2019). At <https:\/\/support.nanotempertech.com\/hc\/en-us\/article_attachments\/18031367832337>"},{"key":"2025111106000702000_2025.11.06.685839v1.69","doi-asserted-by":"publisher","DOI":"10.1002\/pro.3993"},{"key":"2025111106000702000_2025.11.06.685839v1.70","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.67.11.5699-5708.1999"},{"key":"2025111106000702000_2025.11.06.685839v1.71","first-page":"1","article-title":"Development of a non-biased, high-throughput ELISA for the rapid evaluation of immunogenicity and cross-reactivity","volume":"493","year":"2021","journal-title":"J Immunol Methods"},{"key":"2025111106000702000_2025.11.06.685839v1.72","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/174.6.1223"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.11.06.685839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:59:13Z","timestamp":1768471153000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2025.11.06.685839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,8]]},"references-count":72,"URL":"https:\/\/doi.org\/10.1101\/2025.11.06.685839","relation":{},"subject":[],"published":{"date-parts":[[2025,11,8]]},"subtype":"preprint"}}